keloid
Conditions
Interventions
Ring drill+BI+5-FU group:punch excision
MFT+BI+5-F group:CO2 manual fractional laser
Sponsors
Central hospital affiliated to shandong first medical university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1)Participants diagnosed with keloids by the researchers may be treated with betamethasone and 5-fluorouracil injection, CO2 manual fractional laser, or punch excision; (2)maximum diameter = 2 cm but = 5 cm; (3) symmetrical keloids or two keloids with similar morphology at a single site; (4) adult patients aged 18 years or older; (5) Fitzpatrick skin types II-IV; (6) seeking improvement in keloid appearance; and (7) willingness to sign an informed consent form and agree to complete follow-up visits.
Exclusion criteria
Exclusion criteria: (1)Active skin conditions: Subjects with active keloid infections (e.g., ulcers, abscesses), non-healing wounds, or progressive skin diseases (e.g., vitiligo, psoriasis); (2)Recent treatments or surgeries: Subjects who have received or are scheduled to receive treatments or surgeries that may interfere with outcome assessment within the past 3 months (e.g., betamethasone, 5-fluorouracil, verapamil, botulinum toxin, laser therapy, or radiation therapy); (3)Allergies or contraindications: Subjects with known allergies or contraindications to betamethasone, 5-fluorouracil, or lidocaine; (4)Hemostatic disorders: Subjects with a history of bleeding disorders or those who have used or are planning to use anticoagulants, antiplatelet agents, or thrombolytic agents (e.g., warfarin, aspirin) within 14 days prior to screening; (5) Pregnancy or lactation: Women who are pregnant, lactating, or planning to become pregnant (or male subjects unwilling to use adequate contraception) or with a positive pregnancy test at screening;(6) Serious medical conditions: Subjects with a history of serious organ disease or active autoimmune disease; (7)Concurrent clinical trials: Subjects who have participated in any other clinical trial within the past 30 days; (8)Other medical conditions: Subjects with other systemic illnesses or abnormal laboratory findings that, in the investigator's opinion, would make them unsuitable for the study;(9) Inability to comply: Subjects who are unable to communicate or comply with the study protocol; (10)Other reasons: Subjects who, in the investigator's opinion, are not suitable for the study for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vancouver Scar Scale ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient and Observer Scar Assessment Scale; | — |
Countries
China
Contacts
Public Contactsujieyan
Central hospital affiliated to shandong first medical university
Outcome results
None listed